RKTORocket One Inc.
Is Rocket One struggling financially?
Yes, by its own account. Rocket One told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
13/100
Critical
- Sector
- Biotech/Pharma
- Market cap
- $18.6M
- Source filing
- 10-Q 15 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
-
4months
If the burn speeds up
Empty by Oct 2026
-
6months
If it eases off
Empty by Dec 2026
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$7.9M
÷
Cash burned over the last 12 months
$18.9M
What Rocket One told the SEC
…the Company’s current development plan and plans for expansion of its general and administrative infrastructure may be curtailed. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these consolidated financial statements are issued. These unaudited condensed consolidated financial statements have been prepared on a going concern…
Rocket One Inc., Form 10-Q, filed 15 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- 40.3% share-count increase The company issued stock. Each share now owns 28.7% less of the business than a year ago, before any change in the price.
- Cash burn is increasing It is spending 26% more cash per year than it was, so the runway above shortens even if nothing else changes.
Other Biotech/Pharma companies that filed the doubt
- PSTV Cerenome Missing
- INO Inovio Pharmaceuticals $122.0M
- GLSI Greenwich Lifesciences $244.7M
- LTRN Lantern Pharma $29.9M
- RNAZ Transcode Therapeutics $48.6M
- SSII SS Innovations International $718.4M